Although an apparent immune-cold microenvironment in the NFE2L2 mutated NSCLC, durvalumab significantly improves local–regional control and reduces local–regional failure in NFE2L2 mutated patients with NSCLC after chemoradiation [63]. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.